BioJeTay Biotechnology, a subsidiary of Staidson (Beijing) Pharmaceutical Co., Ltd. (SHE: 300204), announced that China’s National Medical Products Administration (NMPA) has formally accepted the clinical trial application (CTA) for a new indication of Bemiltenase alfa – the treatment of major surgical bleeding.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Filing Type | Clinical trial application acceptance – new indication |
| Product | Bemiltenase alfa |
| Proposed Indication | Treatment of major surgical bleeding |
| Acceptance Date | 18 Sep 2026 |
| Existing Approval | Marketing approval in China (Jun 2026) – bleeding episodes in adults with congenital hemophilia A or B with factor VIII or IX inhibitors > 5 BU |
| Next Steps | Initiation of the clinical development program; trial design and timeline not yet disclosed |
Drug Profile & Mechanism of Action
- Molecule: Hemostatic biologic whose active ingredient is purified from the venom of Daboia russelii (Russell’s viper).
- Target: Coagulation factor X – the agent directly activates factor X, initiating the common coagulation pathway to achieve hemostasis.
- Innovation: A globally novel mechanism of action that bypasses inhibited upstream coagulation pathways (factors VIII/IX), enabling clot formation independent of the intrinsic tenase complex.
- Commercial Footprint: Already approved for marketing in China (Jun 2026) for inhibitor‑positive congenital hemophilia A or B (inhibitor titer > 5 Bethesda Units), establishing a first clinical beachhead.
- Indication Rationale: Because factor X activation does not rely on factor VIII or IX, the bypass mechanism provides a pharmacological rationale for extending Bemiltenase alfa into perioperative hemostasis, where rapid, pathway‑independent clotting is critical.
Clinical Context – Unmet Need in Major Surgical Bleeding
- Clinical Setting: Major surgical bleeding remains a leading driver of perioperative transfusion, morbidity, and mortality, particularly in patients with underlying coagulopathy or anticoagulant exposure.
- Current Arsenal: Management relies on blood products, factor concentrates, bypassing agents, and antifibrinolytics – each with limitations in efficacy, thrombotic risk, availability, or patient subpopulations.
- Differentiation Potential: A venom‑derived, direct factor X activator offers a mechanistically distinct hemostatic option for the surgical setting.
- Evidence Status: Clinical trial data for Bemiltenase alfa in major surgical bleeding – not yet disclosed; the program is at the CTA‑acceptance stage.
Market Impact & Outlook
- Lifecycle Expansion: Moving beyond the niche inhibitor‑hemophilia population into major surgical bleeding would substantially broaden Bemiltenase alfa’s addressable patient base and hospital‑channel commercial reach.
- First‑in‑Class Positioning: The globally novel mechanism differentiates the product from recombinant factors and existing bypassing agents, supporting premium positioning in perioperative hemostasis if clinical benefit is demonstrated.
- Staidson Pipeline Value: For Staidson (SHE: 300204), the second‑indication filing strengthens a hemostasis franchise anchored by a product already generating regulatory and commercial momentum in China.
- Regulatory Pathway: CTA acceptance clears the way to enroll and initiate trials; trial start date, design, and endpoints were not disclosed.
- Commercial Outlook: Revenue potential for the surgical‑bleeding indication – not disclosed; dependent on forthcoming clinical results and eventual approval.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development timelines, trial outcomes, regulatory approvals, and commercial expectations for Bemiltenase alfa. Acceptance of a clinical trial application does not guarantee successful trial completion or future marketing approval. Actual results may differ materially due to risks including clinical efficacy and safety findings, regulatory review outcomes, manufacturing scale‑up, and competitive dynamics in the hemostasis market.-Fineline Info & Tech
